melphalan and Hypoparathyroidism

melphalan has been researched along with Hypoparathyroidism* in 1 studies

Other Studies

1 other study(ies) available for melphalan and Hypoparathyroidism

ArticleYear
Hypoparathyroidism during alpha-INF therapy in a patient with multiple myeloma.
    Journal of medicine, 1989, Volume: 20, Issue:5-6

    A 66 year-old woman with multiple myeloma developed hypoparathyroidism during combination chemotherapy with melphalan, prednisolone, and alpha-interferon (INF). Seven weeks after commencement of the therapy, the serum calcium (Ca) level decreased to 7.4 mg/dL, and the phosphorus (P) level increased to 7.2 mg/dL; parathyroid hormone (PTH) was at a critically low level. By 13 weeks after discontinuation of alpha-INF, the levels of Ca, P, and PTH had returned to normal values: 8.6 mg/dL, 4.5 mg/dL, and 310 pg/ml, respectively. These changes suggest a strong correlation between hypoparathyroidism and the administration of alpha-INF. Autoantibodies against the parathyroid gland cell were not present in the serum of this patient by indirect immunofluorescent techniques. The mechanism of hypoparathyroidism by alpha-INF could not be identified, but this is the first case of this condition during alpha-INF therapy.

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hypoparathyroidism; Interferon Type I; Melphalan; Mental Disorders; Multiple Myeloma; Prednisolone

1989